Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.

L Jones; N Hawkins; M Westwood; K Wright; G Richardson; R Riemsma

Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.

L Jones, N Hawkins, M Westwood, K Wright, G Richardson, R Riemsma

Centre for Health Economics

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	1-143
Number of pages	143
Journal	Health technology assessment
Volume	8
Issue number	5
Publication status	Published - 2004

Access to Document

http://www.hta.ac.uk/fullmono/mon805.pdf

Cite this

@article{bba80dbfef4c42c5bbb676b65ff36d48,

title = "Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.",

author = "L Jones and N Hawkins and M Westwood and K Wright and G Richardson and R Riemsma",

year = "2004",

language = "English",

volume = "8",

pages = "1--143",

journal = "Health technology assessment",

issn = "2046-4924",

publisher = "NHS National Institute for Health Research",

number = "5",

}

TY - JOUR

T1 - Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda) for locally advanced and/or metastatic breast cancer.

AU - Jones, L

AU - Hawkins, N

AU - Westwood, M

AU - Wright, K

AU - Richardson, G

AU - Riemsma, R

PY - 2004

Y1 - 2004

M3 - Article

SN - 2046-4924

VL - 8

SP - 1

EP - 143

JO - Health technology assessment

JF - Health technology assessment

IS - 5

ER -